top of page
All Posts


IONS & BIIB Tofersen AdComm on Wednesday!
Summary: The IONS and BIIB AdComm meeting for Tofersen is scheduled for this Wednesday, March 22! Briefing docs were released today...
Mar 20, 20232 min read


Biopharma Pulse - 3/13 - 3/17 Weekly Review
Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...
Mar 17, 20231 min read


Biotech Q1 '23 Catalyst Countdown
We're coming down to the final weeks of Q1 2023. This past week XBI finished green up ~1%, although it still sits in the mid $70's. See...
Mar 17, 20231 min read


CDTX's Rezafungin PDUFA Coming Soon!
Summary: The CDTX PDUFA for Rezafungin to treat candidemia and invasive candidiasis is scheduled for March 22 Positive Phase 3 data from...
Mar 16, 20233 min read


Over 20 Smid-Cap Biopharmas Presenting at AACR 2023!
Summary: The American Association for Cancer Research (AACR) 2023 Annual Meeting will take place from April 14-19, 2023, abstracts...
Mar 15, 20232 min read
Breast Cancer Biotech Stock Catalyst Watchlist
Last updated 3/14/23 Summary: Many exciting breast cancer catalysts are coming throughout the year See the table below for upcoming catalysts and become a Pro member for all catalyst event dates Already a Pro member? Check out the full list of Big Movers ! Table 1. Breast Cancer Catalysts & Assets Sign up for a Pro Membership to see all catalyst event dates! Learn more here Article history: Originally posted 3/14/23
Mar 13, 20231 min read


Biotech Catalyst Watchlist Q1 2023 Part 2
Each week we're posting a countdown of the remaining catalysts left in Q1! Last week was a rough week for biotech's with XBI finishing...
Mar 12, 20231 min read
ACAD Gets approval of Trofinetide for Rett Syndrome
Congrats to $ACAD, its investors, & Rett Syndrome patients on approval of DAYBUE (Trofinetide) for the treatment of Rett Syndrome • Rare genetic disease • 1st approved drug • Supported by Phase 3 Lavender trial data. • No Black Box warning on label • Nice stock runup to approval ~33% • BPIQ Big Mover event • ACAD gets FDA rare pediatric disease voucher • Value ~$100M Competitors from BPIQ Company Screener: $TSHA $AVXL $JAZZ Read more about upcoming PDUFAs https://www.bpiq.com
Mar 11, 20231 min read


Biopharma Pulse - 3/6 - 3/10 Weekly Review
Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...
Mar 10, 20231 min read
NASH & Liver Disease Biotech Stock Catalyst Watchlist
Summary: Many exciting NASH & Liver diseases catalysts are coming throughout the year See the table below for upcoming catalysts and become a Pro member for all catalyst events & dates Already a Pro member? Check out the full list of Big Movers ! Table 1 . NASH & Liver Diseases Catalysts & Assets Sign up for a Pro Membership to see all catalyst event dates! Learn more here Article history: Originally posted 3/10/23; last updated 3/29/23
Mar 10, 20231 min read
Jump start your biotech due diligence
Our platform helps you uncover your next biotech investment opportunity
bottom of page
